Your browser doesn't support javascript.
loading
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
Huber, Rudolf M; Hansen, Karin H; Paz-Ares Rodríguez, Luis; West, Howard L; Reckamp, Karen L; Leighl, Natasha B; Tiseo, Marcello; Smit, Egbert F; Kim, Dong-Wan; Gettinger, Scott N; Hochmair, Maximilian J; Kim, Sang-We; Langer, Corey J; Ahn, Myung-Ju; Kim, Edward S; Kerstein, David; Groen, Harry J M; Camidge, D Ross.
Afiliación
  • Huber RM; Division of Respiratory Medicine and Thoracic Oncology, Department of Medicine V, University Hospital of Munich, Thoracic Oncology Centre Munich, German Centre for Lung Research, Munich, Bavaria, Germany. Electronic address: Huber@med.uni-muenchen.de.
  • Hansen KH; Department of Clinical Oncology, Odense University Hospital, Odense, Denmark.
  • Paz-Ares Rodríguez L; Medical Oncology Department, University Hospital "12 de Octubre," Madrid, Spain.
  • West HL; Thoracic Oncology Program, Swedish Cancer Institute, Seattle, Washington.
  • Reckamp KL; Department of Medical Oncology & Therapeutics Research, City of Hope National Medical Center, Duarte, California.
  • Leighl NB; Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Tiseo M; Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
  • Smit EF; Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, the Netherlands.
  • Kim DW; Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
  • Gettinger SN; Yale Cancer Center, New Haven, Connecticut.
  • Hochmair MJ; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria.
  • Kim SW; Department of Oncology, Asan Medical Center, Seoul, South Korea.
  • Langer CJ; University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania.
  • Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
  • Kim ES; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
  • Kerstein D; Millennium Pharmaceuticals, Inc. (wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, Massachusetts.
  • Groen HJM; University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
  • Camidge DR; University of Colorado Cancer Center, Aurora, Colorado.
J Thorac Oncol ; 15(3): 404-415, 2020 03.
Article en En | MEDLINE | ID: mdl-31756496
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Crizotinib / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Proteínas Quinasas / Crizotinib / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Thorac Oncol Año: 2020 Tipo del documento: Article